J. Carl Barrett
Chief Scientific Officer Precede Biosciences
Seminars
Wednesday 24th September 2025
Panel Discussion: H&E-Based Molecular Profiling: From Bench to Bedside in the Era of Precision Medicine & AI
12:10 pm
- AI-enabled H&E-based molecular profiling has the potential to transform the diagnosis and treatment pathway for cancer and beyond by overcoming key challenges of traditional wet lab methods – such as high cost, time-consuming processes, limited scalability, and variability in reproducibility – through rapid, scalable, and data-driven analysis
- The panel will discuss the enormous potential of utilising AI-enabled H&E-based molecular profiling in Clinics, Drug development and Drug discovery/Research
Wednesday 24th September 2025
Comprehensive Epigenomic Profiling from Plasma to Inform Therapy Selection, Cancer Biology & Drug Development
2:10 pm
- Precede has developed a quantitative assay to measure tumor epigenomic expression of multiple genes using histone modifications indicative of promoter and enhancer activation as well as methylation
- Examples of application of this assay will be shown for ADC and RIC targets to predict response and to identify resistance mechanisms
- Furthermore, the assay can be used to measure estrogen receptor activation to predict response to SERDs
